Adaptive Biotechnologies exec exercises options, sells stock
Adaptive Biotechnologies Corp President and COO Julie Rubinstein reported option exercises and related stock sales.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Adaptive Biotechnologies Corp President and COO Julie Rubinstein reported option exercises and related stock sales. She exercised options to acquire 44,166 shares of common stock at exercise prices of $7.27 and $8.46 per share, then sold 57,180 shares in open-market transactions at weighted average prices generally in the mid‑teens per share. These trades, executed on April 9, 10, and 13, were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025. After the transactions, Rubinstein directly owned 421,174 shares of Adaptive Biotechnologies common stock.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
14 txns
Insider
RUBINSTEIN JULIE
Role
President and COO
Sold
57,180 shs ($758K)
Approx. gross sale proceeds
$758K
Approx. exercise cost
$329K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 8,109 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) | 6,613 | $0.00 | $0.00 |
| Exercise | Common Stock | 8,109 | $7.27 | $59K |
| Exercise | Common Stock | 6,613 | $8.46 | $56K |
| Sale | Common Stock | 15,722 | $12.95 | $204K |
| Sale | Common Stock | 3,338 | $14.08 | $47K |
| Exercise | Stock Option (right to buy) | 14,722 | $0.00 | $0.00 |
| Exercise | Common Stock | 14,722 | $7.27 | $107K |
| Sale | Common Stock | 18,660 | $12.75 | $238K |
| Sale | Common Stock | 400 | $13.48 | $5K |
| Exercise | Stock Option (right to buy) | 14,722 | $0.00 | $0.00 |
| Exercise | Common Stock | 14,722 | $7.27 | $107K |
| Sale | Common Stock | 16,960 | $13.79 | $234K |
| Sale | Common Stock | 2,100 | $14.44 | $30K |
Holdings After Transaction:
Stock Option (right to buy) — 192,936 contracts (Direct);
Common Stock — 421,174 shares (Direct)
Footnotes (9)
- F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
- F2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.40 to $14.38, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F3. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.40 to $14.62, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F4. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.43 to $13.42, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F5. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.44 to $13.53, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F6. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.83 to $13.81, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F7. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.87 to $14.22, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F8. The option is fully vested and exercisable.
- F9. The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Key Figures
Shares sold: 57,180 shares
Options exercised: 44,166 shares
Exercise prices: $7.27 and $8.46 per share
+4 more
7 metrics
Shares sold
57,180 shares
Total open-market sales of common stock reported
Options exercised
44,166 shares
Total underlying common shares from option exercises
Exercise prices
$7.27 and $8.46 per share
Exercise or conversion prices for stock options
Holdings after trades
421,174 shares
Common stock directly owned after all transactions
Sale prices
$12.75–$14.44 per share
Representative reported weighted average sale prices
10b5-1 plan adoption date
November 18, 2025
Date the pre-arranged trading plan was adopted
Net share direction
Net sell of 57,180 shares
transactionSummary netBuySellShares and netBuySellDirection
Key Terms
Rule 10b5-1 trading plan, Stock Option (right to buy), weighted average price, open-market sale, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option (right to buy) financial
""security_title": "Stock Option (right to buy)""
weighted average price financial
"The price reported for this transaction is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market sale financial
""transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative exercise/conversion financial
""transaction_action": "derivative exercise/conversion""
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Adaptive Biotechnologies (ADPT) executive Julie Rubinstein report in this Form 4?
Julie Rubinstein reported a mix of option exercises and share sales. She exercised stock options for 44,166 Adaptive Biotechnologies shares and sold 57,180 shares in open-market transactions, ending with 421,174 shares owned directly after these trades.
How many Adaptive Biotechnologies (ADPT) options did Julie Rubinstein exercise in this filing?
She exercised stock options covering 44,166 shares of Adaptive Biotechnologies common stock. The options had exercise prices of $7.27 and $8.46 per share, converting derivative positions into directly owned shares before related open-market sales were executed.
Were Julie Rubinstein’s Adaptive Biotechnologies (ADPT) trades made under a Rule 10b5-1 plan?
Yes. The Form 4 footnotes state that these transactions were effected pursuant to a Rule 10b5-1 trading plan. The plan was adopted on November 18, 2025, indicating the sales were pre-arranged rather than timed opportunistically by the executive.
What types of securities are involved in Julie Rubinstein’s Adaptive Biotechnologies (ADPT) Form 4?
The filing covers stock options and common stock. Rubinstein exercised stock options described as “Stock Option (right to buy)” into common shares, then sold portions of that common stock in open-market transactions at various weighted average prices.
AI-generated analysis. How Rhea-AI works. Not financial advice.
